Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease

NCT03404115 is registered in ClinicalTrials.gov with Aldeyra Therapeutics, Inc. as lead sponsor.

NCT NCT03404115
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03404115 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center, Phase 2b, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution (0.25% and 0.1%) Compared to Vehicle in Subjects With Dry Eye Disease
Lead sponsor
Aldeyra Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 2, 2018
Completion date
July 11, 2018
Enrollment
300 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

dry eye syndrome